1. Hot tea consumption in combination with excessive smoking or alcohol use was associated with a higher risk for esophageal cancer. 2. In the absence of excessive alcohol use and smoking, daily tea drinking was not linked to increased risk for esophageal cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Esophageal cancer is a concern 
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with Barrett tumors, small tumors T1/2, nodal negative tumors, and Siewert type 1 esophageal tumors.
Volatile Organic Compounds and Esophageal Cancer: Understanding the Implications for Diagnosis and TreatmentSeptember 08, 2017
While utilization of VOCs in the early detection of esophageal cancer has shown promise, future studies should aim at determining which VOCs would be the most specific in diagnosing GI malignancies.
Though a longer overall survival was observed in patients who received pertuzumab plus trastuzumab and chemotherapy, it was not statistically significant.
Neoadjuvant Cisplatin, Epirubicin, and Capecitabine vs Cisplatin and Fluorouracil for Esophageal CancerAugust 07, 2017
Increasing the intensity and duration of neoadjuvant chemotherapy with ECX did not improve survival compared with CF among patients with esophageal adenocarcinoma.
For this study, patients will receive pembrolizumab monotherapy or investigator's choice of paclitaxel, docetaxel, or irinotecan.
Find the latest cancer treatment regimens for esophageal and esophagogastric junction cancers, including drugs such as ECF, cisplatin, and 5-FU.
Bevacizumab is not recommended in conjunction with perioperative chemotherapy for patients with esophageal adenocarcinoma.
Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.
Study authors conclude that FLOT should be an internationally standard option for patients with resectable gastric cancer.
Some data suggest esophageal cancer may be more common among patients diagnosed with achalasia, but there are no relevant screening guidelines.
Adding chemoradiotherapy prior to surgery improves survival versus surgery alone in patients with locally advanced esophageal squamous cell carcinoma (SCC).
Among patients with esophageal squamous cell carcinoma, neoadjuvant treatment with docetaxel, cisplatin, and fluorouracil (DCF) improves survival.
The number of known risk loci for Barrett's esophagus and esophageal adenocarcinoma has doubled.
VSIG10L may be a susceptibility gene for familial syndrome of esophageal adenocarcinoma and Barrett esophagus.
While differences in efficacy between the 3 backbone regimens were nonsignificant, FOLFOX was the best tolerated of tested regimens.
The addition of radiotherapy to neoadjuvant chemotherapy improved histological complete response rate.
For patients with esophageal cancer, venous thromboembolism (VTE) is a risk factor for recurrence.
Those with clinically staged node-negative (cN-) tumors do not derive a significant overall survival benefit vs surgery alone.
Divorce, widowhood, living alone, low educational attainment, and low income increase the risk of each subtype of esophageal and gastric cancer.
Older and younger patients have similar health-related quality of life after esophagectomy for esophageal cancer.
The extent of lymphadenectomy during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific survival.
Neoadjuvant chemoradiotherapy improves overall survival when added to surgery in esophageal or esophagogastric junctional cancer.
Persistent esophageal cancer after definitive chemoradiotherapy has poorer survival when compared with recurrent cancer.
Symptomatic gastroesophageal reflux disease (sGERD) and other factors increase the risk of esophageal adenocarcinoma.
Similarities, Differences Between Esophageal Squamous Cell Carcinomas and Esophageal AdenocarcinomasJanuary 16, 2015
Comprehensive genomic profiling (CGP) shows promise in advanced esophageal squamous cell carcinomas (ESCC) and adenocarcinoma (EAC).
Addition of onartuzumab to mFOLFOX6 for gastroesophageal adenocarcinoma (GEC) did not improve survival.
AMG-337 caused responses in patients with MET-amplified gastroesophageal junction, gastric cancer, and esophageal cancer.
Sarcopenia is a predictor of dose-limiting toxicity in oesophagogastric cancer with neo-adjuvant chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma